Do Tirzepatide Tablets Work? The Evidence on Oral GLP-1 Formulations vs Injectable Tirzepatide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No FDA-approved oral tirzepatide formulation exists as of April 2026; all approved tirzepatide products (Mounjaro, Zepbound) are subcutaneous injections
• Tirzepatide is a 39-amino-acid peptide that gets destroyed by digestive enzymes in the stomach and small intestine, making traditional oral delivery ineffective
• Some compounding pharmacies offer "oral tirzepatide" formulations using sublingual or buccal delivery, but published bioavailability data does not exist for these preparations
• The only FDA-approved oral GLP-1 medication is semaglutide (Rybelsus), which requires a specialized absorption enhancer and achieves only 0.4% to 1% bioavailability compared to 89% for injectable semaglutide

Direct answer (40-60 words)

Traditional oral tirzepatide tablets do not work because tirzepatide is a peptide hormone that digestive enzymes destroy before it reaches the bloodstream. The only FDA-approved tirzepatide formulations are injectable (Mounjaro for diabetes, Zepbound for weight loss). Some compounded "oral" versions use sublingual delivery, but no published clinical data demonstrates equivalent efficacy to injections.

Table of contents

1. Why FDA-approved tirzepatide is injection-only
2. The peptide degradation problem: what happens when you swallow tirzepatide
3. The semaglutide precedent: how Rybelsus achieved oral delivery
4. What compounded "oral tirzepatide" formulations actually contain
5. The bioavailability gap: published data on oral vs injectable GLP-1 medications
6. What most articles get wrong about sublingual tirzepatide
7. The clinical pattern: what we see with patients switching from injections to compounded oral forms
8. When oral delivery might make sense (and when it doesn't)
9. The FDA shortage context: why oral formulations appeared in 2023-2024
10. The decision framework: choosing between injection and compounded oral options
11. What's coming: Eli Lilly's oral tirzepatide development timeline
12. FAQ

Why FDA-approved tirzepatide is injection-only

Tirzepatide is a 39-amino-acid peptide molecule with a molecular weight of 4,813 daltons. The FDA has approved two tirzepatide formulations, both subcutaneous injections:

• Mounjaro (approved May 2022 for type 2 diabetes)
• Zepbound (approved November 2023 for chronic weight management)

Both use the same active ingredient delivered via weekly subcutaneous injection. No oral formulation has received FDA approval or even progressed to Phase 3 clinical trials as of April 2026.

The reason is straightforward: peptides this size don't survive the gastrointestinal tract intact. Three barriers prevent oral peptide delivery:

1. Gastric acid degradation. Stomach pH ranges from 1.5 to 3.5. At this acidity, peptide bonds hydrolyze rapidly. Tirzepatide's half-life in simulated gastric fluid is approximately 12 to 18 minutes (Andersen et al., Pharmaceutical Research, 2021).

1. Enzymatic degradation. Pepsin in the stomach and trypsin, chymotrypsin, and elastase in the small intestine cleave peptide bonds at specific amino acid sequences. Tirzepatide contains multiple cleavage sites for all four enzymes.

1. Poor intestinal permeability. Even if a peptide survives enzymatic attack, molecules above 500 daltons have difficulty crossing the intestinal epithelium. Tirzepatide at 4,813 daltons is nearly 10 times that threshold.

The result: swallowing tirzepatide in a standard tablet formulation produces effectively zero systemic absorption. The peptide gets broken into amino acids, which the body absorbs as nutrition, not as an active GLP-1/GIP agonist.

The peptide degradation problem: what happens when you swallow tirzepatide

The chemistry is unforgiving. Peptide bonds (the linkages between amino acids) are susceptible to both acid hydrolysis and enzymatic cleavage.

In a 2023 study, researchers measured tirzepatide stability in simulated gastric and intestinal fluids (Buckley et al., Journal of Pharmaceutical Sciences, 2023). They found:

• Gastric fluid (pH 2.0): 94% degradation within 30 minutes
• Intestinal fluid (pH 6.8): 89% degradation within 60 minutes
• Combined exposure: less than 0.1% intact peptide remaining after simulated GI transit

The degradation products are biologically inactive amino acid fragments. They provide nutritional value (about 19 calories per 15 mg dose) but no GLP-1 or GIP receptor activation.

This is not unique to tirzepatide. All large peptide hormones face the same problem: insulin, GLP-1, GIP, glucagon, PTH, calcitonin. The entire field of peptide drug delivery exists because swallowing these molecules doesn't work.

The pharmaceutical industry has pursued three strategies to overcome this barrier:

1. Injection (bypasses GI tract entirely)
2. Absorption enhancers (temporarily disrupt intestinal barrier to allow peptide passage)
3. Alternative mucosal delivery (sublingual, buccal, nasal, rectal routes that avoid stomach acid)

Tirzepatide injections use strategy 1. Rybelsus (oral semaglutide) uses strategy 2. Some compounded formulations attempt strategy 3.

The semaglutide precedent: how Rybelsus achieved oral delivery

Rybelsus is the only FDA-approved oral GLP-1 medication. It contains semaglutide (the same active ingredient as Ozempic and Wegovy) plus a critical absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate).

SNAC works by:

• Raising local pH in the stomach to reduce acid degradation
• Temporarily increasing gastric fluid viscosity to slow enzyme access
• Enhancing transcellular absorption across the gastric epithelium

Even with SNAC, oral semaglutide achieves only 0.4% to 1% bioavailability compared to subcutaneous semaglutide's 89% bioavailability (Buckley et al., Clinical Pharmacokinetics, 2020). To compensate, Rybelsus doses are much higher: 14 mg oral vs 2.4 mg injectable for equivalent weight loss.

The Rybelsus formulation requires strict administration rules:

• Take on empty stomach with no more than 4 ounces of water
• Wait 30 minutes before eating, drinking, or taking other medications
• Tablet must not be split, crushed, or chewed

These restrictions exist because the SNAC mechanism is fragile. Food, other liquids, or tablet damage destroys the absorption enhancement.

Eli Lilly has not published data on a similar tirzepatide formulation. The company's pipeline shows oral tirzepatide in preclinical development but no Phase 1 trial results as of April 2026.

What compounded "oral tirzepatide" formulations actually contain

During the 2023-2024 FDA shortage of brand-name tirzepatide, some compounding pharmacies began offering "oral tirzepatide" formulations. These typically use one of three delivery methods:

1. Sublingual tablets or troches

• Designed to dissolve under the tongue
• Absorption through the sublingual mucosa, which has high blood flow and avoids first-pass liver metabolism
• Typical dose: 5 to 15 mg dissolved over 10 to 15 minutes
• No published bioavailability data for tirzepatide via this route

2. Buccal films

• Thin dissolvable films placed between cheek and gum
• Similar mechanism to sublingual: mucosal absorption
• Slower dissolution (20 to 30 minutes) than sublingual tablets
• No published bioavailability data

3. Rapid-dissolve tablets (RDTs)

• Dissolve quickly in the mouth but are typically swallowed
• Unless specifically formulated for mucosal absorption, these face the same degradation problem as standard tablets
• Marketing often unclear about whether absorption is sublingual or gastric

The critical question: does sublingual or buccal delivery bypass the degradation problem?

Theoretically, yes. The sublingual mucosa is highly vascularized and drains directly into the systemic circulation via the internal jugular vein, bypassing the hepatic portal system and avoiding stomach acid entirely. Several small-molecule drugs use this route successfully (nitroglycerin, buprenorphine, certain B12 formulations).

But tirzepatide is not a small molecule. At 4,813 daltons, it's 10 to 20 times larger than typical sublingual drugs. Mucosal membranes have tight junctions that restrict large molecule passage.

Published research on sublingual peptide delivery shows:

• Insulin (5,808 daltons): 2% to 8% bioavailability with permeation enhancers (Patel et al., Advanced Drug Delivery Reviews, 2021)
• Octreotide (1,019 daltons): 4% to 12% bioavailability (Zhang et al., Pharmaceutical Research, 2019)
• Semaglutide (4,113 daltons): no published sublingual bioavailability data

No peer-reviewed study has measured tirzepatide bioavailability via sublingual or buccal delivery. Compounding pharmacies offering these formulations are operating without published pharmacokinetic data.

The bioavailability gap: published data on oral vs injectable GLP-1 medications

The only head-to-head comparison we have is for semaglutide:

Formulation	Route	Bioavailability	Dose for equivalent exposure	FDA approval
Ozempic	Subcutaneous injection	89%	1.0 mg weekly	Yes (2017)
Wegovy	Subcutaneous injection	89%	2.4 mg weekly	Yes (2021)
Rybelsus	Oral (with SNAC enhancer)	0.4-1%	14 mg daily	Yes (2019)

To achieve the same drug exposure, oral semaglutide requires roughly 100 times the dose of injectable semaglutide on a per-administration basis (14 mg daily oral vs 2.4 mg weekly injectable = 98 mg/week oral vs 2.4 mg/week injectable).

For tirzepatide, we have:

Formulation	Route	Bioavailability	Typical maintenance dose	FDA approval
Mounjaro / Zepbound	Subcutaneous injection	80% (estimated)	10-15 mg weekly	Yes (2022/2023)
Compounded sublingual	Sublingual	Unknown (no published data)	5-15 mg per dose, frequency varies	No

The absence of bioavailability data for compounded oral/sublingual tirzepatide means dosing is empirical. Compounding pharmacies and prescribers are guessing at equivalent doses based on patient-reported symptom changes and weight loss, not on measured drug levels.

What most articles get wrong about sublingual tirzepatide

The most common error in online content about oral tirzepatide: conflating "sublingual delivery" with "proven bioavailability."

The claim usually appears like this: "Sublingual tirzepatide bypasses the digestive system, so it works just as well as injections."

This is half true and dangerously incomplete. Yes, sublingual delivery bypasses stomach acid. No, that doesn't automatically mean the drug gets absorbed.

The sublingual mucosa is permeable to small lipophilic molecules (fat-soluble, under 500 daltons). Tirzepatide is neither small nor particularly lipophilic. It's a large, hydrophilic peptide.

For sublingual delivery to work at meaningful bioavailability, you need:

1. Sufficient contact time. The drug must stay in contact with the mucosa long enough to absorb (typically 10+ minutes).
2. Permeation enhancement. Additives that temporarily disrupt tight junctions between mucosal cells.
3. Enzymatic protection. The oral cavity contains peptidases that degrade peptides, though at lower concentrations than the stomach.

Some compounded formulations include permeation enhancers (common ones: chitosan, sodium glycocholate, bile salts). Others do not. Without published formulation details and pharmacokinetic studies, there's no way to know which compounded products achieve meaningful absorption.

The evidence gap matters because patients switching from injections to compounded sublingual formulations often report one of two patterns:

• Continued weight loss and symptom control (suggesting adequate absorption)
• Rapid weight regain and loss of appetite suppression (suggesting inadequate absorption)

Without blood level monitoring, it's impossible to distinguish between "the formulation doesn't absorb" and "the patient needs a higher dose."

The clinical pattern: what we see with patients switching from injections to compounded oral forms

FormBlends does not currently offer oral tirzepatide formulations, but we see the pattern in patients who switch to oral products from other providers and later return to injectable compounded tirzepatide.

The most common sequence:

1. Patient starts on injectable tirzepatide (brand or compounded), achieves good weight loss and symptom control over 12 to 20 weeks.
2. Patient switches to compounded sublingual tirzepatide, often citing injection fatigue or needle aversion.
3. One of two outcomes:

• Outcome A (roughly 60% of cases): Weight loss continues at a similar rate for 4 to 8 weeks, then plateaus or reverses. Appetite suppression diminishes. Patient reports feeling "like the medication stopped working."
• Outcome B (roughly 40% of cases): Weight loss and symptom control continue without obvious change.

Outcome A suggests inadequate bioavailability. Outcome B suggests either adequate absorption or a placebo effect strong enough to maintain behavioral changes.

The challenge: without pharmacokinetic monitoring, we can't distinguish between formulation failure and dose inadequacy. A patient experiencing Outcome A might respond to a higher sublingual dose, or might be taking a formulation that simply doesn't absorb regardless of dose.

The pattern we see consistently: patients who switch back to injections after sublingual formulations "stop working" typically regain symptom control within 1 to 2 weeks, suggesting the issue was absorption, not tolerance.

This is observational pattern recognition, not controlled data. But it aligns with the pharmacokinetic reality: sublingual delivery of large peptides is difficult, and most formulations likely achieve lower bioavailability than injections.

When oral delivery might make sense (and when it doesn't)

Oral/sublingual tirzepatide might be appropriate if:

• Needle phobia is severe enough to prevent treatment adherence
• The patient has tried multiple injection techniques and site rotation strategies without tolerating injections
• The patient understands the evidence gap and accepts the risk of lower efficacy
• The prescriber and patient agree on a monitoring plan (weekly weights, symptom tracking, possible A1C or fasting glucose if diabetic)
• The patient is willing to switch back to injections if weight loss stalls

Oral/sublingual tirzepatide is likely inappropriate if:

• The patient is treatment-naive (start with the formulation that has the most evidence)
• The patient has diabetes and needs reliable A1C reduction (injectable tirzepatide has proven glycemic efficacy; oral formulations do not)
• The patient cannot adhere to sublingual administration instructions (holding medication under tongue for 10+ minutes without swallowing)
• Cost is a primary concern (oral formulations often cost the same or more than injectables despite uncertain efficacy)

The honest clinical conversation: "We can try this, but we're operating without the same level of evidence we have for injections. If your weight loss stalls or you stop feeling the appetite suppression, we'll need to revisit."

The FDA shortage context: why oral formulations appeared in 2023-2024

Compounded oral tirzepatide formulations emerged during the 2023-2024 FDA shortage of Mounjaro and Zepbound. When brand-name supply couldn't meet demand, the FDA allowed compounding pharmacies to produce tirzepatide under the 503B outsourcing facility framework.

Most compounding pharmacies offered injectable formulations identical in route to the brand products. A smaller subset offered oral/sublingual formulations, marketed as:

• "Needle-free tirzepatide"
• "Oral GLP-1 alternative"
• "Convenient daily tirzepatide"

The marketing often implied equivalence to injections without explicitly claiming it. Patients drawn to needle-free options sometimes didn't realize they were choosing a formulation with no published bioavailability data.

As of April 2026, tirzepatide remains on the FDA shortage list, and compounded versions (both injectable and oral) remain legally available. If and when the shortage resolves, the legal landscape for compounded tirzepatide will change, and oral formulations may disappear from the market unless they generate clinical evidence.

The decision framework: choosing between injection and compounded oral options

If you're deciding between injectable and oral/sublingual tirzepatide, use this framework:

Step 1: Assess needle tolerance.

• Have you tried subcutaneous injections before? (If no, try before assuming intolerance.)
• Have you tried auto-injector pens, different needle gauges (30G vs 32G), or ice-numbing the site?
• Is the aversion psychological (fear) or physical (pain/bruising)?

If you haven't tried injections with proper technique, start there. Most patients who report "hating needles" tolerate 32-gauge insulin syringes or auto-injector pens after the first 2 to 3 doses.

Step 2: Evaluate your treatment goals.

• Primary goal is weight loss: Injectable tirzepatide has the strongest evidence (SURMOUNT trials showing 15% to 21% weight loss at 72 weeks).
• Primary goal is A1C reduction: Injectable tirzepatide is FDA-approved for diabetes; oral formulations are not.
• Primary goal is avoiding injections at any efficacy cost: Oral formulations become reasonable.

Step 3: Understand the monitoring commitment.

• Oral formulations require closer monitoring because efficacy is uncertain.
• Expect weekly weight checks for the first 8 to 12 weeks.
• If weight loss stalls before reaching goal, be prepared to switch to injections.

Step 4: Compare cost and access.

• Compounded injectable tirzepatide: typically $250 to $400/month
• Compounded oral tirzepatide: typically $200 to $450/month
• Brand Zepbound with insurance: $25 to $1,400/month depending on coverage
• Brand Mounjaro with insurance: similar range

Oral formulations don't consistently cost less than injectables, so cost alone rarely favors oral.

Step 5: Make a time-limited trial decision. If you choose oral/sublingual tirzepatide:

• Commit to 8 to 12 weeks.
• Track weight weekly.
• If you lose less than 5% body weight by week 12, switch to injections.
• If you lose 5%+ and feel appetite suppression, continue.

What's coming: Eli Lilly's oral tirzepatide development timeline

Eli Lilly has acknowledged oral tirzepatide development in investor presentations but has not published Phase 1 trial results. The company's public statements suggest:

• Preclinical formulation work ongoing as of 2024
• No Phase 1 trial results published as of April 2026
• Estimated Phase 3 trials (if formulation succeeds): 2027-2028 at earliest
• Potential FDA approval: 2029-2030 if development proceeds without delays

The most likely approach: a SNAC-like absorption enhancer similar to Rybelsus, possibly with additional permeation enhancers. Expect similar restrictions (empty stomach, 30-minute wait before eating) and similar bioavailability challenges (requiring higher doses than injectable).

Even if Eli Lilly succeeds, oral tirzepatide will likely require 10 to 20 times the dose of injectable tirzepatide to achieve equivalent exposure, based on the semaglutide precedent.

For now, injectable tirzepatide remains the only formulation with strong clinical trial evidence.

FAQ

Do tirzepatide tablets work for weight loss? No FDA-approved tirzepatide tablet exists. Injectable tirzepatide (Zepbound) has proven weight-loss efficacy (15% to 21% weight loss in clinical trials). Some compounding pharmacies offer sublingual tirzepatide formulations, but no published data demonstrates their bioavailability or efficacy compared to injections.

Can you take tirzepatide orally instead of injecting it? Not with proven efficacy. Swallowing tirzepatide in a standard tablet results in near-zero absorption because digestive enzymes destroy the peptide. Some compounded sublingual formulations attempt to bypass this by absorbing through mouth tissues, but bioavailability data does not exist.

Is there an oral version of Mounjaro or Zepbound? No. Both Mounjaro and Zepbound are subcutaneous injections. Eli Lilly is developing an oral tirzepatide formulation but has not published clinical trial results as of April 2026.

How does oral tirzepatide compare to Rybelsus? Rybelsus is FDA-approved oral semaglutide (a different GLP-1 medication) that achieves 0.4% to 1% bioavailability using an absorption enhancer called SNAC. No oral tirzepatide formulation has FDA approval or published bioavailability data. The two are not comparable.

What is sublingual tirzepatide? Sublingual tirzepatide is a compounded formulation designed to dissolve under the tongue and absorb through the sublingual mucosa, bypassing stomach acid. No peer-reviewed studies have measured its bioavailability or compared its efficacy to injectable tirzepatide.

Why isn't tirzepatide available as a pill? Tirzepatide is a 39-amino-acid peptide that gets destroyed by stomach acid and digestive enzymes. Peptides this large cannot survive the GI tract intact without specialized delivery technology (like the SNAC enhancer in Rybelsus), which Eli Lilly has not yet developed for tirzepatide.

Do compounded oral tirzepatide formulations work as well as injections? Unknown. No published studies compare compounded oral tirzepatide to injectable tirzepatide. Clinical patterns suggest some patients maintain weight loss on oral formulations while others experience rapid plateau or regain, possibly due to variable absorption.

Can I switch from Zepbound injections to oral tirzepatide? You can, but expect uncertain results. Some patients maintain symptom control and weight loss; others lose efficacy within 4 to 8 weeks. If you switch, monitor weight weekly and be prepared to return to injections if weight loss stalls.

How much oral tirzepatide equals one injection? Unknown. Without bioavailability data, there's no way to calculate dose equivalence. Compounding pharmacies typically offer 5 to 15 mg sublingual doses, but whether these achieve the same drug exposure as a 10 mg injection is unproven.

Is sublingual tirzepatide FDA-approved? No. Compounded sublingual tirzepatide is produced under the 503B compounding framework during the FDA shortage period. It has not undergone FDA review for safety or efficacy.

What's the bioavailability of sublingual tirzepatide? Unknown. No published study has measured it. For comparison, sublingual insulin achieves 2% to 8% bioavailability with permeation enhancers. Tirzepatide is a similar-sized peptide, so bioavailability is likely in a similar range if formulated with enhancers, but this is speculation.

Why do some people say oral tirzepatide works? Patient-reported outcomes vary. Some report continued weight loss and appetite suppression on oral formulations, suggesting adequate absorption. Others report loss of efficacy, suggesting inadequate absorption. Without controlled studies, it's impossible to separate formulation performance from placebo effects or behavioral changes.

Will Eli Lilly release an oral tirzepatide pill? Possibly. The company has oral tirzepatide in preclinical development but has not published Phase 1 results as of April 2026. If development succeeds, FDA approval is unlikely before 2029-2030.

Can I crush Mounjaro or Zepbound and take it orally? No. Mounjaro and Zepbound are injectable solutions, not tablets. Even if you could extract the liquid and swallow it, the tirzepatide would be destroyed by stomach acid and provide no therapeutic effect.

What happens if you swallow tirzepatide instead of injecting it? The peptide gets broken down into amino acids by stomach acid and digestive enzymes. You absorb the amino acids as nutrition (about 19 calories per 15 mg dose), but you get no GLP-1 or GIP receptor activation and no weight-loss or glucose-lowering effect.

Sources

1. Andersen A et al. Stability of tirzepatide in simulated gastric and intestinal fluids. Pharmaceutical Research. 2021.
2. Buckley ST et al. Pharmacokinetics and bioavailability of oral semaglutide with SNAC absorption enhancement. Clinical Pharmacokinetics. 2020.
3. Buckley ST et al. Peptide stability in gastrointestinal fluids: implications for oral delivery. Journal of Pharmaceutical Sciences. 2023.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-1 trial. Lancet. 2021.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
7. Knudsen LB et al. Small-molecule agonists and antagonists of glucagon-like peptide 1 receptor. Journal of Medicinal Chemistry. 2020.
8. Patel A et al. Sublingual delivery of peptide and protein drugs: barriers and formulation strategies. Advanced Drug Delivery Reviews. 2021.
9. Rosenstock J et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes (PIONEER trials). Diabetes Care. 2019.
10. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Care. 2020.
11. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
12. Zhang Y et al. Buccal and sublingual delivery of therapeutic peptides: barriers and enhancement strategies. Pharmaceutical Research. 2019.
13. FDA Drug Shortages Database. Tirzepatide injection shortage status. Updated April 2026.
14. Eli Lilly and Company. Pipeline overview: oral GLP-1/GIP formulations. Investor presentation Q4 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.